PracticeUpdate: Conference Series - The Best of ICIEM 2017

THE SIGNS & SYMPTOMS OF COULD BE UNFOLDING IN FRONT OF YOU… BUT WILL YOU SEE THEM IN TIME? 1-3 MPS I OR II Left untreated, patients can face a reduced life expectancy of as little as 10 years. 2,4

Coarse facial features

*Exhibited by patients with MPS I only. 3

TREATMENTS ARE AVAILABLE, SO DON’T DELAY. SUSPECT MPS TODAY. If you suspect MPS I or II proceed to order a urinary metabolic screen (including a urinary GAG test), or refer to your local metabolic physicians for further information and advice.** **Aim to include as much clinical information as possible when requesting a metabolic screen.

MPS: mucopolysaccharidosis; GAG: glycosaminoglycans. Images reproduced with permission. References: 1. Muenzer J et al. Orphanet Journal of Rare Diseases 2017; 12: 82–91. 2. Beck M et al. Genet Med 2014; 16: 759–65. 3. Burton B & Giugliani R. Eur J Pediatr 2012; 171: 631–9. 4. Wraith J et al. Genet Med 2008; 10: 508–16. Sanoˆ-aventis Australia Pty Ltd trading as Sanoˆ Genzyme ABN 31 008 558 807. Talavera Corporate Centre, Building D, 12–24 Talavera Road, Macquarie Park, NSW 2113. GZANZ.ELAP.16.09.0171b(1)e. August 2017. AM7073.